Alkem Laboratories Ltd
NSE:ALKEM
Intrinsic Value
Alkem Laboratories Ltd. engages in the development, manufacture, and sale of pharmaceutical products. [ Read More ]
The intrinsic value of one
ALKEM
stock under the Base Case scenario is
3 719.78
INR.
Compared to the current market price of 5 451.65 INR,
Alkem Laboratories Ltd
is
Overvalued by 32%.
Alkem Laboratories Ltd's market capitalization is 651.8B INR.
ALKEM stock price is 5 451.65 INR.
ALKEM stock (3 719.78 INR) is 32% less than its price (5451.65 INR).
ALKEM stock (2 593 INR) is 52% less than its price (5451.65 INR). Open DCF Valuation
ALKEM stock (4 846.55 INR) is 11% less than its price (5451.65 INR). Open Relative Valuation
ALKEM has downside potential of 8% compared to the average analyst price target.
Open Wall St Estimates
ALKEM's ROIC (Return on Invested Capital) has decreased in the last 3 years from 19% to 16%.
ALKEM's Revenue has grown by 13% over the past 12 months.
ALKEM has positive Net Income for the last twelve months.
ALKEM's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 16%.
ALKEM's ROE (Return on Equity) for the past 12 months is positive and is equal to 17%.
ALKEM has positive Operating Income for the last twelve months.
ALKEM's ROE (Return on Equity) has decreased in the last 3 years from 23% to 17%.
ALKEM's Revenue is forecast to grow at a rate of 12% per year over the next 3 years.
ALKEM has positive three-year average ROIC (Return on Invested Capital): 16%. The company is efficient at using invested capital to generate operating income.
ALKEM's Revenue has been growing by 13% per year for the last 3 years.
ALKEM has positive three-year average ROE (Return on Equity): 18%. The company is efficient at transforming stockholders' equity into net income.
ALKEM has positive Free Cash Flow for the last twelve months.
ALKEM's short-term assets (97B INR) exceed its short-term liabilties (39B INR).
ALKEM has positive Gross Profit for the last twelve months.
ALKEM's long-term assets (149B INR) exceed its long-term liabilties (51B INR).
ALKEM's D/E (Debt to Equity) is very low and is equal to 0.02.
ALKEM has negative Net Debt. This means that the company has more cash and short-term investments (38B INR) than debt (2B INR).
ALKEM's Altman Z-Score is very high and is equal to 9.68.
ALKEM earns more than enough operating income (19B INR) to safely cover interest payments on its debt (974m INR).
Valuation Backtest
Alkem Laboratories Ltd
Run backtest to discover the historical profit from buying and selling
ALKEM
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Alkem Laboratories Ltd
Balance Sheet Decomposition
Alkem Laboratories Ltd
| Current Assets | 96.6B |
| Cash & Short-Term Investments | 38.3B |
| Receivables | 24.6B |
| Other Current Assets | 33.7B |
| Non-Current Assets | 52.6B |
| Long-Term Investments | 6B |
| PP&E | 25.8B |
| Intangibles | 5B |
| Other Non-Current Assets | 15.7B |
| Current Liabilities | 39.1B |
| Accounts Payable | 11.7B |
| Other Current Liabilities | 27.4B |
| Non-Current Liabilities | 11.7B |
| Long-Term Debt | 1.8B |
| Other Non-Current Liabilities | 9.9B |
Earnings Waterfall
Alkem Laboratories Ltd
|
Revenue
|
126.3B
INR
|
|
Cost of Revenue
|
-50.9B
INR
|
|
Gross Profit
|
75.5B
INR
|
|
Operating Expenses
|
-56.5B
INR
|
|
Operating Income
|
19B
INR
|
|
Other Expenses
|
-3.3B
INR
|
|
Net Income
|
15.7B
INR
|
Free Cash Flow Analysis
Alkem Laboratories Ltd
ALKEM Profitability Score
Profitability Due Diligence
Alkem Laboratories Ltd's profitability score is 61/100. The higher the profitability score, the more profitable the company is.
Score
Alkem Laboratories Ltd's profitability score is 61/100. The higher the profitability score, the more profitable the company is.
ALKEM Solvency Score
Solvency Due Diligence
Alkem Laboratories Ltd's solvency score is 93/100. The higher the solvency score, the more solvent the company is.
Score
Alkem Laboratories Ltd's solvency score is 93/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ALKEM Price Targets Summary
Alkem Laboratories Ltd
According to Wall Street analysts, the average 1-year price target for
ALKEM
is 5 005.19 INR
with a low forecast of 3 548.13 INR and a high forecast of 7 119 INR.
Shareholder Return
ALKEM Price
Alkem Laboratories Ltd
| Average Annual Return | 18.49% |
| Standard Deviation of Annual Returns | 24.78% |
| Max Drawdown | -16% |
| Market Capitalization | 651.8B INR |
| Shares Outstanding | 119 565 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Alkem Laboratories Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Alkem Laboratories Ltd. engages in the development, manufacture, and sale of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra and currently employs 16,966 full-time employees. The company went IPO on 2015-12-23. The firm is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The firm operates through pharmaceuticals segment. The firm produces generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals, which it markets in India and approximately 50 countries internationally. The firm offers its products across various therapeutic areas, such as anti-infective, dermatology, diabetology, cardiology, gastroenterology, osteoporosis, Rheumatology, central nervous system (CNS), oncology, urology and gynecology. The firm offers its products under various brands, including Clavam, Pan, Pan-D, Taxim-O, A To Z NS, Xone, Gemcal, Taxim, Sumo, Maxvoid Plus, Tamsukem Plus and Neurokem NT. The firm has approximately 20 manufacturing facilities, of which 18 manufacturing facilities are located in India and two in the United States.
Contact
IPO
Employees
Officers
The intrinsic value of one
ALKEM
stock under the Base Case scenario is
3 719.78
INR.
Compared to the current market price of 5 451.65 INR,
Alkem Laboratories Ltd
is
Overvalued by 32%.
You don't have any saved screeners yet
